Orca Bio is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients’ diseased blood and immune system with a healthy one.
Orca Bio aims to safely and effectively regenerate a healthy blood and immune system for patients with hematological malignancies, genetic diseases and autoimmune disorders.
Orca Bio was founded in 2016 by Ivan Dimov, Nathaniel Fernhoff, and Jeroen Bekaert. The company is headquartered in Menlo Park, California, with an office in Sacramento, California.
Orca Bio is transforming allogeneic cell therapy for patients with blood cancer, genetic diseases and autoimmune disorders.
Orca Bio's products are designed to safely and effectively replace a patient’s diseased blood and immune system with a healthy one. The company’s proprietary therapeutic and manufacturing platforms are exclusively licensed from Stanford University.
Orca's manufacturing platform sorts donor blood with single-cell precision and a high level of purity and speed, enabling the creation of proprietary, optimal therapeutic mixtures of immune and stem cells that have the potential to transform allogeneic cell therapy. The company’s lead product candidate is being evaluated in a multi-center Phase I/II clinical trial in patients with blood cancers.
Orca Bio is backed by Lightspeed Venture Partners, 8VC, DCVC Bio, ND Capital, Mubadala Investment Company, Kaiser Foundation Hospitals and others. The company raised $192M in Series D round on June 17, 2020. This brings Orca's total funding to $300M to date. The round also gives the company a $1B valuation post-money.